LT-010391
/ Shanghai Leadingtac Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 04, 2026
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
(clinicaltrials.gov)
- P1 | N=198 | Not yet recruiting | Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
New P1 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS
1 to 1
Of
1
Go to page
1